We serve Chemical Name:6-Bromo-4-pyrimidinol CAS:1086382-38-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-Bromo-4-pyrimidinol
CAS.NO:1086382-38-8
Synonyms:6-Bromopyrimidin-4-ol;6-bromo-1H-pyrimidin-4-one;4-pyrimidinol, 6-bromo-;6-Bromo-4-pyrimidinol
Molecular Formula:C4H3BrN2O
Molecular Weight:174.983
HS Code:2933599090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:286.6±20.0 °C at 760 mmHg
Density:1.9±0.1 g/cm3
Index of Refraction:1.625
PSA:46.01000
Exact Mass:173.942871
LogP:0.23
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-Bromopyrimidin-4-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Bromo-4-pyrimidinol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Bromopyrimidin-4-ol Use and application,4-pyrimidinol, 6-bromo- technical grade,usp/ep/jp grade.
Related News: Novak noted that the research team did see some improvement in standard brain function tests given to a smaller group of trial participants who had actually been diagnosed with Alzheimer’s. 6-Bromo-4-pyrimidinol manufacturer ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. 6-Bromo-4-pyrimidinol supplier The term active pharmaceutical ingredient may refer to an active chemical within an FDA-regulated drug, or API might mean the entire drug with its active and inactive ingredients. 6-Bromo-4-pyrimidinol vendor With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved. 6-Bromo-4-pyrimidinol factory With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved.
